SEMPRA - EQUITY AND EARNINGS PER COMMON SHARE (Tables)

3 Months Ended

Mar. 31, 2026

Earnings Per Share [Abstract]

Schedule Of Sale Of Stock

The principal terms of these forward sale agreements at March 31, 2026 are as follows:

FORWARD SALE AGREEMENTS UNDER THE ATM PROGRAM THAT REMAIN SUBJECT TO FUTURE SETTLEMENT
(Dollars in millions, except per share amounts)
Date of agreement	Number of shares subject to agreement	Number of shares that remain to be settled	Initial forward price per share	Expected net proceeds(1)	Forward purchaser	Sales commissions	Final settlement date
November 18, 2024	2,909,274	2,909,274	$92.1546	$268	Bank of America, N.A.	$2.4	June 30, 2026(2)
February 26, 2025	2,087,317	2,087,317	$70.6593	$147	Wells Fargo Bank, N.A.	$1.3	March 31, 2027

(1)    Expected net proceeds assumes full physical settlement, is net of sales commission but does not deduct other equity issuance costs, and is subject to certain adjustments pursuant to the applicable forward sale agreement.

(2)    On April 7, 2026, the forward sale agreement was amended to extend the final settlement date to December 31, 2027.

Schedule Of Transfers (To) From Noncontrolling Interest

The following table summarizes net income attributable to Sempra and transfers (to) from CRNCI and NCI, which shows the effects of changes in Sempra’s ownership interest in its subsidiaries on Sempra’s shareholders’ equity.

NET INCOME ATTRIBUTABLE TO SEMPRA AND TRANSFERS (TO) FROM CRNCI AND NCI
(Dollars in millions)
	Three months ended
	March 31, 2026
Sempra:
Net income attributable to Sempra	$	1,037
Transfers (to) from CRNCI and NCI:
Increase in shareholders’ equity from allocation of interests(1)	6
Net transfers (to) from CRNCI and NCI	6
Change from net income attributable to Sempra and transfers (to) from CRNCI and NCI	$	1,043

(1)    We describe the allocation of interests in Note 10.

Schedule of Earnings Per Share, Basic and Diluted

EARNINGS PER COMMON SHARE COMPUTATIONS
(Dollars in millions, except per share amounts; shares in thousands)
	Three months ended March 31,
	2026		2025
Sempra:
Numerator:
Earnings attributable to common shares	$	1,037	$	906
Denominator:
Weighted-average common shares outstanding for basic EPS(1)	653,589		651,992
Dilutive effect of common shares sold forward	482		—
Dilutive effect of stock options and RSUs(2)	1,417		1,026
Weighted-average common shares outstanding for diluted EPS	655,488		653,018
EPS:
Basic	$	1.59	$	1.39
Diluted	$	1.58	$	1.39

(1)    Includes 385 and 516 fully vested RSUs held in our deferred compensation plan in the three months ended March 31, 2026 and 2025, respectively. These fully vested RSUs are included in weighted-average common shares outstanding for basic EPS because there are no conditions under which the corresponding shares will not be issued.

(2)    Due to market fluctuations of both Sempra common stock and the comparative indices used to determine the vesting percentage of our total shareholder return performance-based RSUs, which we discuss in Note 14 of the Notes to Consolidated Financial Statements in the Annual Report, dilutive RSUs may vary widely from period-to-period.